title: eIF2B-related disorders: antenatal onset and involvement of multiple organs.
abstract: Leukoencephalopathy with vanishing white matter, also called "childhood ataxia with central nervous system hypomyelination," is the first human disease related to mutations in any of the five genes encoding subunits of eukaryotic initiation factor eIF2B or any translation factor at all. eIF2B is essential in all cells of the body for protein synthesis and the regulation of this protein synthesis under different stress conditions. It is surprising that mutations in the eIF2B genes have been reported to lead to abnormalities of the white matter of the brain only, although it has been shown recently that ovarian failure may accompany the leukoencephalopathy. Another surprising observation is that the onset of the disease varies from early childhood to adulthood, with the exception of Cree leukoencephalopathy, a disease related to a particular mutation in one of the eIF2B genes, which invariably has its onset within the first year of life. We analyzed the eIF2B genes of nine patients with an antenatal- or early-infantile-onset encephalopathy and an early demise and found mutations in eight of the patients. In addition to signs of a serious encephalopathy, we found oligohydramnios, intrauterine growth retardation, cataracts, pancreatitis, hepatosplenomegaly, hypoplasia of the kidneys, and ovarian dysgenesis. Until now, no evidence had been found for a genotype-phenotype correlation, but the consistently severe phenotype in affected siblings among our patients and in Cree encephalopathy patients suggests an influence of the genotype on the phenotype.
authors.affiliation: Department of Child Neurology, Free University Medical Center, Amsterdam, The Netherlands. ms.vanderknaap@vumc.nl
authors.forename: Marjo S
authors.initials: MS
authors.lastname: van der Knaap
authors.forename: Carola G M
authors.initials: CG
authors.lastname: van Berkel
authors.forename: Jochen
authors.initials: J
authors.lastname: Herms
authors.forename: Rudy
authors.initials: R
authors.lastname: van Coster
authors.forename: Martina
authors.initials: M
authors.lastname: Baethmann
authors.forename: Sakkubai
authors.initials: S
authors.lastname: Naidu
authors.forename: Eugen
authors.initials: E
authors.lastname: Boltshauser
authors.forename: Michèl A A P
authors.initials: MA
authors.lastname: Willemsen
authors.forename: Barbara
authors.initials: B
authors.lastname: Plecko
authors.forename: Georg F
authors.initials: GF
authors.lastname: Hoffmann
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Proud
authors.forename: Gert C
authors.initials: GC
authors.lastname: Scheper
authors.forename: Jan C
authors.initials: JC
authors.lastname: Pronk
mesh_terms: D000015:Abnormalities, Multiple / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D017668:Age of Onset; D000595:Amino Acid Sequence; D000818:Animals; D001921:Brain / Q000002:abnormalities / Q000378:metabolism / Q000473:pathology; D001927:Brain Diseases / Q000150:complications* / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D004252:DNA Mutational Analysis; D020717:Eukaryotic Initiation Factor-2B / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D005838:Genotype; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009154:Mutation / Q000235:genetics; D009928:Organ Specificity; D010641:Phenotype
chemical_list: D020717:Eukaryotic Initiation Factor-2B